Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants.
Abstract: Assayed factors included the amount of HBV-DNA in the liver tissues; genotype; and the presence of the HBV precore stop codon G1896A mutation, basal core promoter A1762T/G1764A mutation, and pre-S deletions/stop codon mutation.
Prevalent HBV point mutations and mutation combinations at BCP/preC region and their association with liver disease progression.
Abstract: The top three multi-mutations were A1762T/G1764A (36%), A1762T/G1764A/G1896A (11%) and T1753(A/C)/A1762T/G1764A/G1896A (8%).
Result: In univariate binary logistic regression analysis, all the top five high occurrence mutations seemed to relate to ALD, including T1753A/C (OR = 3.2, 95% CI: 1.3-7.9, P = 0.013), A1762T (OR = 3.1, 95% CI: 1.5-6.5, P = 0.003), G1764A (OR = 4.8, 95% CI: 2.1-10.9, P < 0.001), T1803A/G (OR = 5.1, 95% CI: 1-25.4, P = 0.058
A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma.
Abstract: By multiple logistic regression analysis, the presence of cirrhosis, A1762T/G1764A and G1899A mutations were independently associated with the risk of HCC.
Abstract: CONCLUSION: These data suggested that A1762T/G1764A and G1899A mutations were associated with the development of HCC in Thai patients.
Abstract: RESULTS: The prevalence of T1753C/A, A1762T/G1764A and G1899A mutations were significantly higher in the Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants.
PMID: 21186523
2010
Zhonghua shi yan he lin chuang bing du xue za zhi
Abstract: A1762T/G1764A double mutation rate was 40.0% (18/45), 84.4% (38/45), 73.5% (36/49) and 92.6% (25/27) respectively in different groups.
Abstract: CONCLUSION: A1762T/G1764A double mutation has a close relationship with the progress of HBV-infection diseases, but is not specific to patients with ACLF.
Abstract: HBV DNA level (log) of patients with A1762T/G1764A double mutation was 5.68 +/- 1.36, lower than but having no significant statistic difference compared to patients without the double mutation (6.14 +/- 1.81, P = 0.075).
Abstract: However, A1762T/G1764A double mut
Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants.
Abstract: BACKGROUND/AIMS: Although there have been a few reports regarding the effect of basal core promoter (BCP) double mutations (A1762T and G1764A) on hepatitis B viral loads, the association remains uncertain.
Introduction: One of the most critical changes is the appearance of double mutations at nt 1762 (A-T) and 1764 (G-A) in the BCP.
Association between genomic heterogeneity of hepatitis B virus and intrauterine infection.
Abstract: The A1762T and G1764A mutations in the basal core promoter (BCP) region and the G1896A mutation in the precore (PC) region of hepatitis B virus (HBV) genome are found commonly in HBeAg-negative patients.
Introduction: The most common BCP mutations are A to T at nt 1762 and G to A at nt 1764 (T1762/A1764).
Discussion: These HBeAg positive patients of genotype C infection also had a higher prevalence of the A1762T/G1764A
Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations.
Discussion: The high replication capacity was mapped to nucleotides 1574-1986, where 7 core promoter mutations are present: G1751T, T1753A, G1757A, A1762T, G1764A, C1766T, and T1768A.
Discussion: The most common core promoter mutations, A1762T/G1764A, had been found by other investigators to moderately increase genome replication.
Discussion: Thus, clone 4B contains a combination of T1753C, A1762T, G1764A, and C1766T mutat
Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
Abstract: Of the 17 patients, 3 carried both pre-C (G1896A) and BCP (A1762T/G1764A) mutants, 1 pre-C only and 1 BCP only.
Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Abstract: RESULTS: The frequency of patients with detectable PC stop codon mutation (G1896A), basal core promoter mutation (A1762T/G1764A) and pre-S deletion at baseline was 22.4%, 21.6% and 12.1%, respectively.
HBV mutation literature information.
PMID: 
2010
Hepatology (Baltimore, Md.)
Browser Board
Co-occurred Entities
Filtrator
ViMRT